The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

키워드

참고문헌 (38)

1. Kris MG, "Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs", JAMA, 311, pp.1998~2006 (2014)
2. Shi Y, "A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology(PIONEER)", J Thorac Oncol, 9, pp.154~162 (2014)
3. Hsu KH, "Identification of five driver gene mutations in patients with treatment-naive lung adenocarcinoma in Taiwan", PLoS One, 10, pp.e0120852~ (2015)
4. Kuan FC, "Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers : a systematic review and meta-analysis", Br J Cancer, 113, pp.1519~1528 (2015)
5. Lee CK, "Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival", J Natl Cancer Inst, 109, pp.djw279~ (2017)
6. Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7) : a phase 2B, open-label, randomised controlled trial", Lancet Oncol, 17, pp.577~589 (2016)
7. Wu YL, "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer(ARCHER 1050) : a randomised, open-label, phase 3 trial", Lancet Oncol, 18, pp.1454~1466 (2017)
8. Soria JC, "Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer", N Engl J Med, 378, pp.113~125 (2018)
9. Ramalingam SS, "Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC", N Engl J Med, 382, pp.41~50 (2020)
10. Ito K, "A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset : CJLSG1903", ESMO Open, 6, pp.100115~ (2021)
11. Chen DS, "Oncology meets immunology : the cancer-immunity cycle", Immunity, 39, pp.1~10 (2013)
12. Stinchcombe TE, "Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non-small cell lung cancer : a phase 2 randomized clinical trial", JAMA Oncol, 5, pp.1448~1455 (2019)
13. Seto T, "Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations(JO25567) : an open-label, randomised, multicentre, phase 2 study", Lancet Oncol, 15, pp.1236~1244 (2014)
14. Saito H, "Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer(NEJ026) : interim analysis of an open-label, randomised, multicentre, phase 3 trial", Lancet Oncol, 20, pp.625~635 (2019)
15. Maemondo M, "NEJ026 : final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations", J Clin Oncol, 38, pp.15~ (2020)[DOI]
16. Nakagawa K, "Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer(RELAY) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.1655~1669 (2019)
17. Zhou Q, "CTONG 1509: phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC", Ann Oncol, 30(Suppl 5), pp.v603~ (2019)
18. Ninomiya T, "Phase 2 study of afatinib alone or combined with bevacizumab in chemonaive patients with advanced non-small-cell lung cancer harboring EGFR mutations : AfaBev-CS study protocol", Clin Lung Cancer, 20, pp.134~138 (2019)
19. Hsu PC, "The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma : a multicenter observational study", Pharmaceuticals(Basel), 13, pp.331~ (2020)
20. Wang CC, "A real-world analysis of patients with untreated metastatic epidermal growth factor receptor(EGFR)-mutated lung adenocarcinoma receiving first-line erlotinib and bevacizumab combination therapy", Oncol Ther, 9, pp.489~503 (2021)
21. Tsai JS, "EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer : a propensity score matching analysis", J Formos Med Assoc, 120, pp.1729~1739 (2021)
22. Tsai TH, "RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer", Eur Respir J, 39, pp.677~684 (2012)
23. Su KY, "Pretreatment epidermal growth factor receptor(EGFR)T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer", J Clin Oncol, 30, pp.433~440 (2012)
24. Ninomiya T, "A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations : Okayama Lung Cancer Study Group Trial 1404", Lung Cancer, 115, pp.103~108 (2018)
25. Ninomiya T, "Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404", Ann Oncol, 30(Suppl 5), pp.v626~ (2019)
26. Ko R, "Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations", Transl Lung Cancer Res, 10, pp.183~192 (2021)
27. Harrison PT, "Rare epidermal growth factor receptor(EGFR)mutations in non-small cell lung cancer", Semin Cancer Biol, 61, pp.167~179 (2020)
28. Hong S, "Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer", JAMA Oncol, 4, pp.739~742 (2018)
29. Jiao XD, "The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base", J Thorac Dis, 11, pp.4507~4515 (2019)
30. 김유진, "Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib", Cancer Research and Treatment, 51(2), pp.502~509 (2019), 대한암학회
31. Yu HA, "Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer", Clin Cancer Res, 27, pp.992~1002 (2021)
32. Akamatsu H, "Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M-mutated non-small cell lung cancer previously treated with epidermal growth factor receptor-tyrosine kinase inhibitor : West Japan Oncology Group 8715L phase 2 randomized clinical trial", JAMA Oncol, 7, pp.386~394 (2021)
33. Yu HA, "Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers : a phase 1", 2 single-group open-label trial, 2020, pp.6, 1048~1054
34. Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)
35. Yen-Hsiang Huang, "The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma", Cancer Research and Treatment, 50(4), pp.1294~1303 (2018), 대한암학회
36. Hochmair MJ, "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : final analysis of the GioTag study", Future Oncol, 16, pp.2799~2808 (2020)
37. Reck M, "Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer : AVAil", J Clin Oncol, 27, pp.1227~1234 (2009)
38. Mok TS, "Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial", Asia Pac J Clin Oncol, 7(Suppl 2), pp.4~12 (2011)

관련 논문AI추천